Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions

Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, mo...

Full description

Bibliographic Details
Authors: Pavord, ID, Wechsler, ME, Busse, WW, Domingo, C, Xia, CM, Gall, R, Pandit-Abid, N, Jacob-Nara, JA, Radwan, A, Rowe, PJ, Deniz, Y
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:dnet:r-i3pt______::ba3f78c9e9f397db708e591d8b4fd0fe
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/6490
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004307011&doi=10.1016%2Fj.jacig.2025.100474&partnerID=40&md5=5f29e7fe8668b0c9e863f084f894a6b4
Access Level:Open access
Keyword:Dupilumab
asthma
FENO
asthma exacerbation
lung function
asthma control
asthma-related quality of life
early response
id ES_79a7b03415256b7fbcb3d83dd4affb4d
oai_identifier_str oai:dnet:r-i3pt______::ba3f78c9e9f397db708e591d8b4fd0fe
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dupilumab efficacy in patients with type 2 asthma and early FENO level reductionsPavord, IDWechsler, MEBusse, WWDomingo, CXia, CMGall, RPandit-Abid, NJacob-Nara, JARadwan, ARowe, PJDeniz, YDupilumabasthmaFENOasthma exacerbationlung functionasthma controlasthma-related quality of lifeearly responseBackground: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. Objective: This analysis assessed dupilumab efficacy in patients from QUEST who enrolled in TRAVERSE and were stratified by a reduction in fractional exhaled nitric oxide (FENO) level by week 2 of QUEST. Methods: Patients with an FENO level of at least 25 ppb at parent study baseline (PSBL) were defined as those with or without a minimally important FENO level reduction/response (a >= 20% reduction in patients with an FENO level of >= 50 ppb and a reduction of >10 ppb in those with an FENO level of <50 ppb at PSBL) by week 2 of QUEST. We assessed annualized severe exacerbation rates (AERs) and changes from PSBL in prebronchodilator FEV1 value, 5-item Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score. Results: During QUEST, dupilumab (compared with placebo) reduced AER by 58% to 59% across FENO response subgroups (unadjusted AER 5 0.392-0.523 for dupilumab vs 1.052-1.280 for placebo) and improved prebronchodilator FEV1 value regardless of FENO response. These improvements were sustained during TRAVERSE, with a slightly greater magnitude in FENO responders. Dupilumab also improved 5-item Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores independently of FENO responses. Conclusion: Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early reduction in FENO level. Greater improvements were seen in patients with an early reduction in FENO level, but patients without such a reduction also showed favorable outcomes during their treatment with dupilumab.ELSEVIER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/6490https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004307011&doi=10.1016%2Fj.jacig.2025.100474&partnerID=40&md5=5f29e7fe8668b0c9e863f084f894a6b4Journal of Allergy and Clinical Immunology: GlobalISSN: 27728293reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-i3pt______::ba3f78c9e9f397db708e591d8b4fd0fe2026-06-21T15:30:37Z
dc.title.none.fl_str_mv Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
title Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
spellingShingle Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
Pavord, ID
Dupilumab
asthma
FENO
asthma exacerbation
lung function
asthma control
asthma-related quality of life
early response
title_short Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
title_full Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
title_fullStr Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
title_full_unstemmed Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
title_sort Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
dc.creator.none.fl_str_mv Pavord, ID
Wechsler, ME
Busse, WW
Domingo, C
Xia, CM
Gall, R
Pandit-Abid, N
Jacob-Nara, JA
Radwan, A
Rowe, PJ
Deniz, Y
author Pavord, ID
author_facet Pavord, ID
Wechsler, ME
Busse, WW
Domingo, C
Xia, CM
Gall, R
Pandit-Abid, N
Jacob-Nara, JA
Radwan, A
Rowe, PJ
Deniz, Y
author_role author
author2 Wechsler, ME
Busse, WW
Domingo, C
Xia, CM
Gall, R
Pandit-Abid, N
Jacob-Nara, JA
Radwan, A
Rowe, PJ
Deniz, Y
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dupilumab
asthma
FENO
asthma exacerbation
lung function
asthma control
asthma-related quality of life
early response
topic Dupilumab
asthma
FENO
asthma exacerbation
lung function
asthma control
asthma-related quality of life
early response
description Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. Objective: This analysis assessed dupilumab efficacy in patients from QUEST who enrolled in TRAVERSE and were stratified by a reduction in fractional exhaled nitric oxide (FENO) level by week 2 of QUEST. Methods: Patients with an FENO level of at least 25 ppb at parent study baseline (PSBL) were defined as those with or without a minimally important FENO level reduction/response (a >= 20% reduction in patients with an FENO level of >= 50 ppb and a reduction of >10 ppb in those with an FENO level of <50 ppb at PSBL) by week 2 of QUEST. We assessed annualized severe exacerbation rates (AERs) and changes from PSBL in prebronchodilator FEV1 value, 5-item Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score. Results: During QUEST, dupilumab (compared with placebo) reduced AER by 58% to 59% across FENO response subgroups (unadjusted AER 5 0.392-0.523 for dupilumab vs 1.052-1.280 for placebo) and improved prebronchodilator FEV1 value regardless of FENO response. These improvements were sustained during TRAVERSE, with a slightly greater magnitude in FENO responders. Dupilumab also improved 5-item Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores independently of FENO responses. Conclusion: Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early reduction in FENO level. Greater improvements were seen in patients with an early reduction in FENO level, but patients without such a reduction also showed favorable outcomes during their treatment with dupilumab.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/6490
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004307011&doi=10.1016%2Fj.jacig.2025.100474&partnerID=40&md5=5f29e7fe8668b0c9e863f084f894a6b4
url https://i3pt.portalinvestigacion.com/publicaciones/6490
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004307011&doi=10.1016%2Fj.jacig.2025.100474&partnerID=40&md5=5f29e7fe8668b0c9e863f084f894a6b4
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv Journal of Allergy and Clinical Immunology: Global
ISSN: 27728293
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411365651742720
score 15.81155

Similar Items